ENA 2020: Existing heart drugs may help cancer patients respond better to PD(L)1 immunotherapy
Researchers have found that a class of commonly-used heart drugs may also improve patients’ responses…
Browsing: PD(L)1 immunotherapy
Trending
- Making Telehealth Human – Podcast
- Sign Up for The Oncology Newsletter | Our free weekly news roundup
- Donors key to discovery of potential new combination therapy for leukaemia
- Major collaboration aims to eliminate cervical cancer in the Western Pacific
- Supporting older Australians with cancer
- Cytosponge: AI could triage patients at risk of early stage oesophageal cancer
- The OJC Episode 29: Neoadjuvant Therapy in Melanoma with Georgina Long
- AACR 2021: Neoadjuvant nivolumab plus chemotherapy increased pathological complete response rate in CheckMate-816 lung cancer trial
- AACR 2021: Unselected autologous tumour infiltrating lymphocyte therapy shows early promise in patients with metastatic melanoma
- AACR 2021: Novel approach to PRMT5 inhibition that selectively targets the PRMT5/MTA complex in MTAP-deleted cancer models
